采集并记录患者确诊NSCLC时的临床资料,包括年龄、性别、肿瘤分期、病理类型、基因[表皮生长因子受体(epidermal growth factor receptor, EGFR)/间变性淋巴瘤激酶(anaplastic lymphoma kinase, ALK)/ROS原癌基因1受体酪氨酸激酶(ROS proto-oncogene 1 receptor tyrosine kinase, ROS1)]结果、有无胸腔积液及肿瘤治疗(包括化疗、靶向治疗、抗血管治疗、免疫治疗等)、治疗疗效和生存状态。. The gene discussed is ALK; the disease is non-small cell lung carcinoma.